Compare Amylx Pharmaceuticals Inc (AMLX) vs Booking Holdings Inc (BKNG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Booking Holdings Inc — how do they compare? Amylx Pharmaceuticals Inc trades at $22.57 (market cap $2.60B), while Booking Holdings Inc trades at $211.91 (market cap $159.49B). The key difference: Booking Holdings Inc is far larger — about 61.3× Amylx Pharmaceuticals Inc's market cap, and Booking Holdings Inc pays a 0.79% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | BKNG | |
|---|---|---|
Market Cap | $2.60B | $159.49B |
Sector | Health | Consumer Cyclical |
52-Week High | $24.19 | $228.83 |
52-Week Low | $7.82 | $154.13 |
Enterprise Value | $2.36B | $162.97B |
Dividend Yield | — | 0.79% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $23.35, down 1.18% on the day, with strong analyst support (90.9% buy ratings) and a $30 consensus price target. The stock shows bullish technical momentum with moving averages supporting upward movement, though RSI levels indicate potential overbought conditions. Recent Q2 2026 earnings missed expectations with a loss of $0.39 per share, but the company maintains significant cash reserves through 2028 and anticipates key Phase 3 trial results for avexitide in late August/September 2026.
The investment case hinges on successful clinical trial outcomes and future revenue generation, with current negative profitability metrics offset by strong institutional backing and promising pipeline catalysts. Key risks include clinical trial failures, ongoing financial losses, and competitive pressures in the biotech sector.
BKNG trades at $212.26, down 0.29% on the day, with a bullish technical outlook per moving averages and support at $209. The company reported strong Q2 2026 earnings, beating EPS estimates with $2.54 versus $2.43 expected, and revenue growth continues, supported by resilient travel demand. Analyst consensus is a Buy with a $239.31 price target, reflecting optimism despite geopolitical volatility noted in recent news.
The stock presents a favorable risk-reward profile with solid fundamentals, including a 25.53% net income margin and 23.58 P/E ratio, but faces risks from debt levels and competition. Upside is driven by earnings beats and AI integration, while macroeconomic headwinds and high valuation multiples warrant caution for investors seeking entry points.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Booking Holdings Inc
Booking is the world's largest online travel agency by revenue, offering booking and payment services for hotel and alternative accommodation rooms, airline tickets, rental cars, restaurant reservations, cruises, experiences, and other vacation packages. The company operates a number of branded travel booking sites, including Booking.com, Agoda, OpenTable, and Rentalcars.com, and has expanded into travel media with the acquisitions of Kayak and Momondo. Transaction fees for online bookings account for the bulk of revenue and profits.
Read more on BKNG →
